Life ScienceCompany
Astellas Pharma M&A Summary
Astellas Pharma has acquired 15 companies, including 5 in the last 5 years. A total of 1 acquisition came from private equity firms. It has also divested 2 assets.
Astellas Pharma’s largest acquisition to date was in 2023, when it acquired IVERIC bio for $5.9B. It’s largest disclosed sale occurred in 2015, when it sold Astellas Pharma - Global Dermatology to LEO Pharma A/S for $761M. Astellas Pharma has acquired in 6 different US states, and 4 countries. The Company’s most targeted sectors include life science (87%) and medical products (7%).
Astellas Pharma Business Overview
Where is Astellas Pharma headquartered?
Astellas Pharma is headquartered in Tokyo, Japan.
What is Astellas Pharma’s revenue?
Astellas Pharma disclosed revenue of 1,603,672M JPY for 2024 and 1,518,619M JPY for 2023.
How many employees does Astellas Pharma have?
Astellas Pharma has 14,754 employees.
What sector is Astellas Pharma in?
Astellas Pharma is a life science company.
When was Astellas Pharma founded?
Astellas Pharma was founded in 1923.
M&A Summary
-
M&A Total Activity16
- M&A Buy Activity15
- M&A Sell Activity2
- Total Sectors Invested 2
- Total Countries Invested 4
- M&A Buy/Sell Connections 4
- M&A Advisors 6
Unlimited Searches
